Lindis biotech presents encouraging data from bladder cancer trial
Data revealed that 100% of patients achieved a complete remission with no recurrence - News - PharmaTimes
Source: pharmatimes.com
📰 Planegg News
Page 32 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
EQS-News: MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimers Disease
EQS-News: MorphoSys AG / Key word(s): Study results MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for...
Source: businessinsider.com
MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer's Disease Seite 1
14.11.2022 - GRADUATE studies did not meet primary endpointPLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 14, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the ... Seite 1
Jean Paul Kress Ihre Einstellungen Constellation Pharmaceuticals Inc Chief Executive Officer Clinical Trials Constellation Pharmaceuticals
Source: wallstreet-online.de
EQS-Adhoc: Ad hoc: MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer's Disease Seite 1
14.11.2022 - EQS-Ad-hoc: MorphoSys AG / Key word(s): Study results Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease 14-Nov-2022 / 07:12 CET/CEST Disclosure of an inside ... Seite 1
Source: wallstreet-online.de
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: MorphoSys AG / Key word(s): MiscellaneousGSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis   27.10.2022 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich,...
United States Thomas Biegi Julia Neugebauer Eamonn Nolan Exchange Commission American College Of Rheumatology
Source: pharmiweb.com
MorphoSys AG: GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program
Source: finanznachrichten.de
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting I
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors 27.10.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Re...
Source: pharmiweb.com
MorphoSys AG: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat Supporting Its Potential Application in a Broad Array of Advanced Tumors
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR SymposiumPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys
Source: finanznachrichten.de
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Ad-hoc: MorphoSys AG / Key word(s): Change in Forecast Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Fin...
United States Julia Neugebauer Exchange Commission Distribution Services Updates Financial Guidance Product Sales
Source: businessinsider.com
Investegate |MorphoSys AG Announcements | MorphoSys AG: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Investegate announcements from MorphoSys AG, Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
United States Julia Neugebauer Exchange Commission Distribution Services Updates Financial Guidance Product Sales
Source: investegate.co.uk